Video

A Journal Club for Patients with Prostate Cancer VL

Search

Discussion Between Expert Clinicians and Patients on the EMBARK Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg Details Matthew Cooperberg, alongside patient advocates Stan Rosenfeld, Bruce Zweig, Nathan Roundy, and Leszek Izdebski, engages in a comprehensive Q&A session with Neal Shore, Stephen Freedland, and Rana McKay. They explore the potential applications of enzalutamide for low-risk prostate cancer patients on active surveillance, referencing findings from the ENACT and EMBARK trials. Dr. Shore emphasizes th...
EMBARK Trial: Enzalutamide Monotherapy & Combination Therapy for High-Risk Prostate Cancer - Stephen Freedland, Neal Shore, & Rana McKay Details Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland an...
ProtecT Trial 15-Year Data Shows Low Prostate Cancer Mortality Across Therapies for Localized Disease, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg Details Matthew Cooperberg introduces the inaugural patient-oriented journal club for patients diagnosed with prostate cancer. This patient journal club aims to highlight prostate cancer research, selected trials, and pivot to open discussion between expert clinicians and patients. The 15-year update from the ProtecT trial, led by Professors Freddie Hamdy and Jenny Donovan is the selected trial for this s...
Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg Details In this Prostate Cancer Patient Journal Club discussion, Matthew Cooperberg and Jenny Donovan address quality-of-life outcomes from the ProtecT trial's surveillance group. Jenny notes that those who did not progress avoided radical treatment impacts, with no significant quality of life difference compared to radically treated patients. Group discussion includes side effects and global variability...